Clinical trials: Minimal Change Disease, open to volunteers
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
- Trial name
- RESULT (NCT06500702)
- Testing
- frexalimab, brivekimig, rilzabrutinib
- Where
- 79 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Nephrotic Syndrome
INSIGHT (Insight Into Nephrotic Syndrome)
INSIGHT is a longitudinal study of childhood nephrotic syndrome to determine genetic, serologic and environmental factors contributing to nephrotic syndrome and disease progression.
- Trial name
- INSIGHT (NCT01605266)
- Where
- 4 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- The Hospital for Sick Children
Minimal Change Disease (MCD)
A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)
OBELIX-NEPHROSIS (NS) The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab.
- Trial name
- OBELIX-NS (NCT07710157)
- Testing
- Obinutuzumab Injection, Predniso(lo)ne
- Where
- 6 sites in Austria, France and 1 more
- Volunteers
- 48 people
- Sponsor
- Medical University Innsbruck
Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis
- Trial name
- NCT07499700
- Testing
- BAT4406F
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Bio-Thera Solutions
Nephrotic Syndrome in Children, Minimal Change Disease
taVNS for FRNS in Children
Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications.
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- kidNEY-VNS (NCT05588063)
- Testing
- Transcutaneous auricular vagus nerve stimulation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Idiopathic Nephrotic Syndrome (INS)
Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes
Renal biopsy (RB) is the reference diagnostic procedure for Idiopathic Nephrotic Syndrome (INS). It is an invasive procedure, particularly risky during the acute phase of nephrotic syndrome when anticoagulation therapy is…
- Trial name
- DNI-SNI (NCT06820866)
- Where
- France
- Volunteers
- 265 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ANCA Associated Vasculitis, Extramembranous Glomerulopathy
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
- Conditions
- ANCA Associated Vasculitis, Extramembranous Glomerulopathy, Nephrotic Syndrome, Minimal Change, Interstitial Nephritis
- Trial name
- PROTECT-Fi (NCT07010250)
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nephrotic Syndrome
Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
This retrospective study is aimed at evaluating the levels of circulating anti-nephrin autoantibodies in patients with INS, including those with MCD/FSGS and in patients who have experienced relapse of FSGS post-transplant…
- Trial name
- BLINDER (NCT06334692)
- Testing
- In-house ELISA, and ELISA kits from "DBA Italy" (Abbexa).
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Urinary Incontinence
Clinically Important or Just Statistically Significant? MCID for DVISS and PIN-Q in Children With UI
The goal of this study was to determine the Minimal Clinically Important Difference (MCID) for the Dysfunctional Voiding and Incontinence Symptom Score (DVISS) and the Pediatric Incontinence Questionnaire (PIN-Q) in children with…
- Trial name
- NCT07242898
- Testing
- Standard Urotherapy (SU)
- Volunteers
- 100 people
- Sponsor
- Artvin Coruh University
Colon Adenocarcinoma, Colorectal Cancer
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon…
- Trial name
- NCT04920032
- Testing
- TAS-102, Irinotecan, Standard Treatment
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, Irvine
Minimal Change Disease
Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in…
- Trial name
- NCT06405100
- Testing
- Supportive care+Prednisone, Supportive care+Tacrolimus+Ripertamab, Supportive care+Ripertamab
- Volunteers
- 81 people
- Sponsor
- Air Force Military Medical University, China
Colorectal Cancer
Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)
Surgery is the main treatment method for colon cancer. About 50% of patients can be cured with surgery alone. For colon cancer with high-risk stage II or III after surgery, the current guidelines recommend 3-6 months after…
- Trial name
- AFFORD (NCT05427669)
- Testing
- mFOLFOXIRI, mFOLFOX6
- Volunteers
- 340 people
- Sponsor
- Yanhong Deng
Glomerular Disease, Minimal Change Disease
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Glomerulonephritis (GN) generates an enormous individual and social economic burden. However, the therapeutic options are largely based on clinical and pathological parameters and the individual response to therapy or prognosis…
- Conditions
- Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy
- Trial name
- KORNERSTONE (NCT03929887)
- Testing
- Kidney Biopsy
- Where
- 6 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Hospital
Parkinson Disease
Determination of the Minimal Detectable Change of the Parkinson's Disease Questionnaire-8
This study is conducted to determine how many units of improvement the Parkinson's Disease Questionnaire-8 (PDQ-8), used to evaluate the quality of life of Parkinson's patients, should have to express a significant change in the…
- Trial name
- NCT06487364
- Testing
- Rehabilitation
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Emre Şenocak
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and…
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Trial name
- RESOLVE (NCT05650619)
- Testing
- Biospecimen collection, Data collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Michigan
Idiopathic Nephrotic Syndrome
Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study
This study will compare a short-term course (12 week) glucocorticoid regimen with the Conventional 24-week regimen as originally proposed by KDIGO.
- Trial name
- NCT07151456
- Testing
- Conventional 24-week glucocorticoid regimen, short-term course (12 week) glucocorticoid regimen
- Where
- China
- Volunteers
- 224 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Parkinson Disease
Minimal Clinically Important Difference of the Box and Block Test in Parkinson
The aim of this study is to examine the level of clinical change in gross manual skills of Parkinson's patients who receive conventional physiotherapy.
- Trial name
- NCT06490809
- Testing
- Physiotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Emre Şenocak
Fluid Overload, Glomerulosclerosis, Focal Segmental
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome.
- Conditions
- Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy
- Trial name
- Prepare-NS (NCT05505500)
- Testing
- Interview
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Michigan
Nephrotic Syndrome, Membranous Nephropathy
Circulating Factors in Nephrotic Syndrome
A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.
- Conditions
- Nephrotic Syndrome, Membranous Nephropathy, Minimal Change Disease, Primary Focal Segmental Glomerulosclerosis
- Trial name
- NCT06315504
- Testing
- Observation
- Volunteers
- 104 people
- Sponsor
- Iain Bressendorff